Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abbvie Inc (ABBV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 105,080,664
  • Shares Outstanding, K 1,593,580
  • Annual Sales, $ 25,638 M
  • Annual Income, $ 5,953 M
  • 36-Month Beta 1.52
  • Price/Sales 4.11
  • Price/Cash Flow 11.81
  • Price/Book 23.16

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.12 +4.47%
on 04/18/17
67.50 -2.31%
on 04/27/17
-0.04 (-0.06%)
since 03/28/17
3-Month
59.27 +11.25%
on 01/30/17
67.50 -2.31%
on 04/27/17
+5.94 (+9.90%)
since 01/27/17
52-Week
55.06 +19.76%
on 10/28/16
68.12 -3.20%
on 08/15/16
+4.74 (+7.75%)
since 04/28/16

Most Recent Stories

More News
AbbVie (ABBV) Q1 Earnings Beat Estimates, Revenues Up Y/Y

AbbVie Inc. (ABBV) reported better-than-expected results in the first-quarter of 2017. The company surpassed both earnings and sales expectations.

HSKA : 108.25 (+2.88%)
GALE : 0.59 (-4.84%)
JNJ : 123.47 (-0.22%)
ABBV : 65.94 (-0.20%)
AbbVie (ABBV) Beats Earnings and Revenue in Q1

AbbVie's first-quarter earnings came in at $1.28 per share, beating the Zacks Consensus Estimate of $1.26.

ABBV : 65.94 (-0.20%)
AbbVie Reports First-Quarter 2017 Financial Results

AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2017.

ABBV : 65.94 (-0.20%)
A Tax Cut in Progress

A Tax Cut in Progress

EVR : 73.75 (+0.27%)
PCH : 45.05 (-4.05%)
BMRN : 95.84 (-0.44%)
ABBV : 65.94 (-0.20%)
TWOU : 45.40 (+0.67%)
5 Fantastic Earnings Charts

Tracey brings you the companies with the best earnings charts each week.

PYPL : 47.72 (+1.21%)
EFX : 135.31 (-0.65%)
ABBV : 65.94 (-0.20%)
RTN : 155.21 (-0.67%)
AMGN : 163.32 (+0.37%)
Pharma Stocks Q1 Earnings Roster for Apr 27: CELG, ABBV, BMY

Celgene, AbbVie and Bristol-Myers Squibb are expected to report earnings on Apr 27.

CELG : 124.05 (+0.06%)
JNJ : 123.47 (-0.22%)
ABBV : 65.94 (-0.20%)
BMY : 56.05 (+0.68%)
BIIB : 271.21 (-1.94%)
Gilead (GILD) Q1 Earnings: Stock Likely to Beat Estimates?

Gilead Sciences Inc. (GILD) is scheduled to report first-quarter 2017 results on May 2, after the market closes.

ABBV : 65.94 (-0.20%)
GILD : 68.55 (-0.04%)
ICPT : 112.35 (-0.78%)
AMGN : 163.32 (+0.37%)
Biogen (BIIB) Q1 Earnings & Sales Top, Spinraza Sales Strong

Biogen Inc. (BIIB) reported better-than-expected results in the first-quarter of 2017. The company surpassed expectations both for earnings and sales.

JNJ : 123.47 (-0.22%)
ABBV : 65.94 (-0.20%)
AMGN : 163.32 (+0.37%)
BIIB : 271.21 (-1.94%)
Is Pain Ahead for Healthcare ETFs After Weak JNJ Q1?

Results from Johnson and Johnson could be a warning sign for other drug makers, which are scheduled to report this week and the next.

VHT : 140.13 (+0.26%)
JNJ : 123.47 (-0.22%)
MRK : 62.33 (-0.40%)
IYH : 158.60 (+0.25%)
FHLC : 36.33 (+0.11%)
ABBV : 65.94 (-0.20%)
AMG : 165.59 (-0.05%)
GILD : 68.55 (-0.04%)
SPY : 238.08 (-0.22%)
AMGN : 163.32 (+0.37%)
PFE : 33.92 (+0.18%)
BMY : 56.05 (+0.68%)
Is Pain Ahead for Healthcare ETFs After Weak JNJ Q1?

Results from Johnson and Johnson could be a warning sign for other drug makers, which are scheduled to report this week and the next.

VHT : 140.13 (+0.26%)
JNJ : 123.47 (-0.22%)
MRK : 62.33 (-0.40%)
IYH : 158.60 (+0.25%)
FHLC : 36.33 (+0.11%)
ABBV : 65.94 (-0.20%)
AMG : 165.59 (-0.05%)
GILD : 68.55 (-0.04%)
SPY : 238.08 (-0.22%)
AMGN : 163.32 (+0.37%)
PFE : 33.92 (+0.18%)
BMY : 56.05 (+0.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation...

See More

Support & Resistance

2nd Resistance Point 66.78
1st Resistance Point 66.36
Last Price 65.94
1st Support Level 65.48
2nd Support Level 65.02

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.